[1] A WELLSTEIN G G B D Palm. Affinity and selectivity of beta-adrenoceptor antagonists in vitro.[J]. Journal of Cardiovascular Pharmacology, 1986, 8 Suppl 11: S36-40. DOI:
10.1097/00005344-198511001-00006[2] DOROTA POZAROWSKA Zbigniew D Piotr Pozarowski. Cytometric assessment of cytostatic and cytotoxic effects of topical glaucoma medications on human epithelial corneal line cells†[J]. Cytometry Part B: Clinical Cytometry, 2009, 78B 2: 130-137. DOI:
10.1002/cyto.b.20493[3] N. SHARIF. Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes.[J]. Journal of Ocular Pharmacology and Therapeutics, 2001, 26 1: 305-317. DOI:
10.1089/108076801753162726[4] GLYN CHIDLOW Neville N O José Melena. Betaxolol, a β1-adrenoceptor antagonist, reduces Na+ influx into cortical synaptosomes by direct interaction with Na+ channels: comparison with other β-adrenoceptor antagonists[J]. British Journal of Pharmacology, 2009, 130 4: 759-766. DOI:
10.1038/sj.bjp.0703369 
